IXICO (LSE:IXI) Margin of Safety % (DCF FCF Based): N/A (As of Jun. 24, 2026)


What is IXICO Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

IXICO's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

LSE:IXI vs VRTX, REGN, ALNY: Margin of Safety % (DCF FCF Based) Comparison

For the Biotechnology subindustry, IXICO's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IXICO Margin of Safety % (DCF FCF Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IXICO's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where IXICO's Margin of Safety % (DCF FCF Based) falls into.


IXICO Business Description

Address 15 Long Lane, 4th Floor, Griffin Court, London, GBR, EC1A 9PN
IXICO PLC provides neuroscience imaging and biomarker analytics services, using its proprietary AI-driven platform to help advance the treatment of neurological disorders and reduce the uncertainties associated with drug discovery, development and monitoring. It operates as an imaging contract research organization, supporting clinical trials for neurological disorders by processing and analyzing imaging data. Its platform is used to measure biomarkers associated with diseases such as Alzheimer's, Huntington's, and Parkinson's.